Insulin lispro biosimilar - Sanofi

Drug Profile

Insulin lispro biosimilar - Sanofi

Alternative Names: Admelog; Insulin lispro Sanofi; SAR-342434

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Sep 2017 The US FDA issues tentative approval to insulin lispro biosimilar 100 units/ml in Type-1 and Type-2 diabetes mellitus (In adults, In children)
  • 31 Jul 2017 Registered for Type-1 diabetes mellitus (In children, In adults) in Iceland, Norway, Liechtenstein (SC)
  • 31 Jul 2017 Registered for Type-2 diabetes mellitus (In adults, In children) in Iceland, Liechtenstein, Norway (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top